# OnCo record anal (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/anal/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "anal" ;
  schema:name "Anal cancer (squamous cell carcinoma)"@en ;
  schema:description "An HPV-caused cancer of the anal canal that is usually cured without surgery by combined chemotherapy and radiation. Prevention (HPV vaccination, screening of high-risk groups) and immunotherapy for advanced disease are the new fronts."@en ;
  schema:url <https://onco.cc/cancers/anal/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Anal_cancer> ;
  owl:sameAs <http://www.wikidata.org/entity/Q484827> ;
  schema:citation <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1414>, <https://doi.org/10.1056/NEJMoa2201048>, <https://www.cancer.gov/types/anal/patient/anal-treatment-pdq> ;
  onco:tag "gap-fill", "gastrointestinal", "hpv" ;
  onco:related <https://onco.cc/cancers/urethral/> ;
  onco:technologies <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/hpv-vaccine/>, <https://onco.cc/technologies/hpv-testing/>, <https://onco.cc/technologies/precancer-ablation/>, <https://onco.cc/technologies/cthpv-dna/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/pdl1/> ;
  onco:drugs <https://onco.cc/drugs/mitomycin/>, <https://onco.cc/drugs/fluorouracil/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/retifanlimab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/gardasil-9/> ;
  onco:companies <https://onco.cc/companies/incyte/>, <https://onco.cc/companies/merck/>, <https://onco.cc/companies/bms/>, <https://onco.cc/companies/oncolytics-biotech/> ;
  onco:pathways <https://onco.cc/pathways/pd1-checkpoint/> ;
  onco:terms <https://onco.cc/terms/hpv-p16/>, <https://onco.cc/terms/clinical-complete-response/> ;
  onco:pipeline <https://onco.cc/drugs/retifanlimab/>, <https://onco.cc/technologies/cthpv-dna/>, <https://onco.cc/technologies/hpv-vaccine/> ;
  onco:standardOfCare <https://onco.cc/technologies/hpv-testing/>, <https://onco.cc/technologies/precancer-ablation/>, <https://onco.cc/technologies/hpv-vaccine/>, <https://onco.cc/trials/anchor/>, <https://onco.cc/drugs/mitomycin/>, <https://onco.cc/drugs/fluorouracil/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/drugs/retifanlimab/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/trials/pod1um-303/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/pembrolizumab/> .